Last reviewed · How we verify
Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)
Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) is a Combination inhaler (ICS/LAMA/LABA) Small molecule drug developed by Thammasat University. It is currently FDA-approved. Also known as: Trelegy.
FUV is a triple-combination inhaler that integrates a corticosteroid (fluticasone furoate), a long-acting muscarinic antagonist (umeclidinium), and a long-acting beta2-adrenergic agonist (vilanterol) to provide synergistic bronchodilation and anti-inflammatory effects.
Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) is a combination inhaler developed by Thammasat University for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The drug combines a corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta2-adrenergic agonist to provide comprehensive bronchodilation and anti-inflammatory effects. Despite its potential benefits, FUV has not yet received FDA approval, and its development status remains in the pipeline. Common side effects include nasopharyngitis, upper respiratory tract infection, and headache. The drug's safety profile and efficacy are currently being evaluated in clinical trials.
At a glance
| Generic name | Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) |
|---|---|
| Also known as | Trelegy |
| Sponsor | Thammasat University |
| Drug class | Combination inhaler (ICS/LAMA/LABA) |
| Target | Airway inflammation and bronchoconstriction |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
The combination of these three components targets multiple pathways involved in COPD pathophysiology, reducing airway inflammation and bronchoconstriction.
Approved indications
Pipeline indications
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Headache
Key clinical trials
Patents
| Patent | Expiry | Type |
|---|---|---|
| 8347879 | 2028-07-15 | Formulation |
| 8062264 | 2026-04-05 | Formulation |
| 8147461 | 2028-10-15 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) CI brief — competitive landscape report
- Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) updates RSS · CI watch RSS
- Thammasat University portfolio CI
Frequently asked questions about Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)
What is Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)?
How does Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) work?
Who makes Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)?
Is Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) also known as anything else?
What drug class is Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) in?
What development phase is Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) in?
What are the side effects of Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)?
What does Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) target?
Related
- Drug class: All Combination inhaler (ICS/LAMA/LABA) drugs
- Target: All drugs targeting Airway inflammation and bronchoconstriction
- Manufacturer: Thammasat University — full pipeline
- Therapeutic area: All drugs in Respiratory
- Also known as: Trelegy
- Compare: Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) vs similar drugs
- Pricing: Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) cost, discount & access